Navigation Links
The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
Date:3/14/2008

ABBOTT PARK, Ill., March 13, 2008 Data published today in The Lancet from ABSORB, the worlds first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year. These one year results for Abbott's bioabsorbable everolimus eluting stent were consistent with performance demonstrated by the system at 6 months, as previously reported in October 2007. Abbott's prospective, non-randomized, ABSORB clinical trial is designed to evaluate the overall safety and performance of a fully bioabsorbable everolimus eluting stent out to 5 years.

"Abbott's bioabsorbable everolimus eluting stent has demonstrated excellent clinical safety out to one year in patients with coronary artery disease," said Patrick W. Serruys, M.D., Ph.D., Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study. "The positive results from this clinical trial form a strong basis for the development of additional bioabsorbable stent platforms with the potential to eliminate some of the restrictions posed by metallic stents in areas such as vessel imaging and vessel remodeling."

At 6 months, the overall MACE rate in the ABSORB trial was 3.3 percent (one patient, n=30) and late loss, a measure of reduction in vessel lumen diameter after stenting, was 0.44 mm. At one year, the overall MACE rate in the ABSORB trial was consistent with results at 6 months (one patient, 3.3 percent, n=30; 3.4 percent adjusted for one patient who withdrew from follow-up, known to be event free at 1 year, n=29). MACE is a composite measure of cardiac death, heart attack and re-treatment of a diseased lesion (ischemia-driven target lesion revascularization) in the ABSORB trial. Abbott's bioabsorbable everolimus eluting stent also demonstrated 100 percent procedural success and 94 percent device success in the ABSORB trial.

"Patients and physicians like the idea of a stent that does its job and is then absorbed away," said John A. Ormiston, M.B., Ch.B., cardiologist at Auckland City Hospital, in Auckland, New Zealand and principal investigator in the ABSORB trial. "Abbott's bioabsorbable stent has the potential to hold an artery open long enough for healing to occur, and we would expect an artery that is healed to function as it did before it became diseased."

Abbott is the only company with a fully bioabsorbable drug eluting coronary stent in clinical trials. Abbotts bioabsorbable everolimus eluting coronary stent is made of polylactic acid, a proven biocompatible material that is commonly used in medical implants such as dissolvable sutures. As with a metallic stent, Abbotts bioabsorbable stent is designed to restore blood flow in clogged coronary arteries, and to provide mechanical support until the blood vessel heals. Unlike a metallic stent, however, a bioabsorbable stent is designed to be slowly metabolized by the body and completely absorbed over time.

"Abbott's bioabsorbable drug eluting stent system is a great example of scientific innovation leading to a breakthrough treatment for heart disease that has the potential to improve patients' lives," said John M. Capek, Ph.D., executive vice president of medical devices, Abbott. "We look forward to continuing to evaluate the safety and effectiveness of our bioabsorbable stent platform in additional patients in the coming months."


'/>"/>

Contact: Karin Bauer
408-845-3887
Abbott Vascular
Source:Eurekalert

Related biology news :

1. World-leading journal publishes special issue on UN/GA
2. DOE publishes update of plan: Facilities for the Future of Science: A 20-Year Outlook
3. University biologist publishes book on bird speciation
4. NHLBI issues first US von Willebrand Disease clinical practice guidelines
5. Iowa State researchers help piece together the corn genomes first draft
6. First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills
7. Map is first to track global human influences on ocean ecosystems
8. First map of threats to marine ecosystems shows all the worlds oceans are affected
9. First datasets for national biomass and carbon dataset now available
10. Stanford researchers make first direct observation of 3-D molecule folding in real time
11. Genes and environment interact in first graders to predict physical but not social aggression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology: